Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Prostate Cancer Stocks Recent News

Date Stock Title
Oct 4 SNY Market Chatter: Sanofi Healthcare Suitors Revise Offers Amid Talc Liability Concerns
Oct 4 SNY Sanofi consumer health unit bidders revising offers over talc powder concerns - report
Oct 4 SNY Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
Oct 4 SNY Sanofi Healthcare Bidders Revising Offers Over Talc Concerns
Oct 4 SNY GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
Oct 4 SNY Sanofi, GSK, CSL Tapped to Expand US Bird Flu Vaccine Supply
Oct 4 SNY GSK, Sanofi, CSL said to win $72M U.S. bird flu vaccine contract
Oct 4 SNY Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Oct 4 SNY Sanofi inks $1B deal to sell autoimmune disorder therapy
Oct 4 SNY Sanofi’s rare disease drug finds yet another home
Oct 4 SNY Thermo Fisher plant making Astra/ Sanofi RSV drug reportedly breached FDA rules
Oct 4 SNY Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
Oct 4 SNY Texas sues major PBMs, pharma companies over high insulin prices
Oct 2 EXEL EXEL vs. CSLLY: Which Stock Is the Better Value Option?
Oct 2 PDSB PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
Oct 1 SNY Update: Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit
Oct 1 SNY Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit
Oct 1 SNY Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers
Sep 30 SNY Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sep 28 SNY Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags